Another Generic Drug Maker Challenges Plavix Patent
The lawsuit, filed last week in the Southern District of New York, comes in the wake of Cobalt’s filing with the U.S. Food and Drug Administration (FDA) of an abbreviated new drug application (ANDA) for clopidrogel bisulfate, the active ingredient of Plavix. The application was filed with a so-called “Paragraph IV” certification.
Generics drug applicants must include with their ANDAs...
To view the full article, register now.